Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 43/2026 October 25, 2026
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
Dual Enzyme Blockade Weakens Prostate Cancer Tumors and Enhances Treatment Effectiveness
/in Preclinical Research/by MaxResearchers have identified two enzymes that serve as critical guardians of prostate cancer cell survival, opening new avenues for enhancing treatment outcomes in one of the most common cancers affecting men worldwide. The study, published in the Proceedings of the National Academy of Sciences, demonstrates that blocking these molecular chaperones can destabilize cancer cells and […]
Phase 3 Trial: Xaluritamig (AMG 509) Plus Abiraterone in mCRPC
/in Clinical Trial, Metastatic, Phase 3/by MaxA large international Phase 3 clinical trial is evaluating a new treatment combination for men with metastatic castration-resistant prostate cancer (mCRPC) who have not yet undergone chemotherapy (in castration resistant settings, prior chemo is allowed). The study is testing xaluritamig (AMG 509) together with abiraterone acetate against the investigator’s choice of standard therapies (docetaxel, cabazitaxel, […]
UPDATE: Phase 1 Trial of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
/in Clinical Trial, Metastatic, Phase 1/by MaxA new Phase 1 clinical study, known as the ARTISAN trial, is evaluating an investigational lead-212 alpha radioligand therapy targeting prostate-specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC). We discussed AB001 in a previous article; the trial has now been approved, and its full details are available. The therapy combines a […]
Phase 1/2 Study: New Combination Therapy Combines Tulmimetostat (DZR123) and JSB462 (aka Luxdegalutamide aka ARV-766)
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxUPDATE: VIR-5500 Advances to Third Part of Phase 1 Study With Promising Early Results
/in Clinical Trial, Metastatic, Phase 1/by MaxNew Cancer Vaccine is Promising in Preclinical Research
/in Immunotherapy, Preclinical Research/by MaxAMPLITUDE: a Phase 3 Clinical Trial of Niraparib Combined with Abiraterone Acetate for HRR-Deficient Metastatic Castration-Sensitive Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxScientists Develop “Velcro” Cancer Treatment That Works Across Many Tumor Types
/in Immunotherapy, Preclinical Research/by MaxResearchers at the University of California, Irvine have developed an innovative cancer immunotherapy called GlyTR, a new class of treatment that uses a “velcro-like” mechanism to target sugar molecules abundantly present on cancer cells. Their findings were published in September 2025 in the prestigious journal Cell, marking a significant advancement in cancer immunotherapy. Traditional immunotherapies […]